C L Tso
Overview
Explore the profile of C L Tso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
289
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Pang S, Dannull J, Kaboo R, Xie Y, Tso C, Michel K, et al.
Cancer Res
. 1997 Feb;
57(3):495-9.
PMID: 9012480
The prostate-specific antigen (PSA) promoter (PSA-P) has been identified, characterized, and determined to be tissue specific. Compared with high expression of the genomic PSA gene in prostate cells, expression of...
12.
Sokoloff M, Tso C, Kaboo R, Nelson S, Ko J, dOrey F, et al.
J Urol
. 1996 Nov;
156(5):1560-6.
PMID: 8863538
Purpose: To improve on current staging and monitoring methods for prostate cancer, we applied the technique of quantitative polymerase chain reaction to measure the degree of tumor burden in the...
13.
Sokoloff M, Tso C, Kaboo R, Taneja S, Pang S, DeKernion J, et al.
Cancer
. 1996 May;
77(9):1862-72.
PMID: 8646686
Background: Cytokines exert cytostatic and immunomodulatory effects on carcinoma cells. Growth inhibition of human prostate carcinoma by cytokines has been demonstrated both in vitro and in vivo, whereas the cellular...
14.
Belldegrun A, Tso C, Kaboo R, Pang S, Pierce W, DeKernion J, et al.
J Immunother Emphasis Tumor Immunol
. 1996 Mar;
19(2):149-61.
PMID: 8732698
Combination therapy with systemically administered interleukin-2 (IL-2) and tumor infiltrating lymphocytes (TIL) demonstrates significant clinical activity in some patients with metastatic renal cell carcinoma (RCC). The objective of this study...
15.
Economou J, Belldegrun A, Glaspy J, Toloza E, Figlin R, Hobbs J, et al.
J Clin Invest
. 1996 Jan;
97(2):515-21.
PMID: 8567975
Adoptive immunotherapy with tumor-infiltrating lymphocytes (TIL) and IL-2 appears to produce dramatic regressions in patients with metastatic melanoma and renal cancer. However, the in vivo mechanism of TIL function is...
16.
Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, et al.
Hum Gene Ther
. 1995 Nov;
6(11):1417-26.
PMID: 8573614
We have cloned and characterized a 620-bp fragment of DNA that flanks 5' of the prostate-specific antigen (PSA) gene from a prostate cancer patient. Using DNA transfection, the efficacy of...
17.
Hathorn R, Tso C, Kaboo R, Pang S, Figlin R, Sawyers C, et al.
Cancer
. 1994 Oct;
74(7):1904-11.
PMID: 7521786
Background: Continuous local delivery of interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) via gene transfer appears to be more effective than systemic therapy in preventing the growth of human renal cell carcinoma...
18.
Linna T, Moody D, Feeney L, Okarma T, Tso C, Belldegrun A
Immunol Ser
. 1994 Jan;
61:175-8.
PMID: 8011741
No abstract available.
19.
Belldegrun A, Pierce W, Kaboo R, Tso C, Shau H, Turcillo P, et al.
J Urol
. 1993 Nov;
150(5 Pt 1):1384-90.
PMID: 8411405
Murine models demonstrate therapeutic synergy for the combination of interleukin-2, interferon-alpha and tumor-infiltrating lymphocytes. We treated 11 patients with metastatic renal cell carcinoma with a novel regimen consisting of in...
20.
Belldegrun A, Tso C, Sakata T, Duckett T, Brunda M, Barsky S, et al.
J Natl Cancer Inst
. 1993 Feb;
85(3):207-16.
PMID: 8423625
Background: Combination therapy with systemically administered interleukin-2 (IL-2) and interferon alpha (IFN-alpha) has resulted in long-term objective remissions in 30% of patients with metastatic renal cell carcinoma (RCC), but toxic...